Abraxis BioScience, Inc. and The Scripps Research Institute (TRSI) have entered an exclusive licensing agreement for the worldwide development and commercialization of an epothilone therapeutic for the treatment of cancer. Epothilones are a new class of microtubule-stabilizing agents, which bind to the tubulin pathway to inhibit the growth and proliferation of cancer cells. Under the terms of the agreement, Abraxis has rights to eleven potential drug candidates for preclinical evaluation ...